Results for this period
Full year1 April 2025–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Despite the impact of drug price revisions and other factors, the company focused on expanding new and core products. Core operating profit declined due to lower gross profit and higher selling, general and administrative expenses and research and development expenses. IFRS operating profit benefited from an increase in other income, but the company recorded impairment losses in connection with the discontinuation of development.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥291,624 million (YoY -2.8%) |
| Operating profit | ¥47,797 million (YoY +2.0%) |
| Ordinary income | ¥47,442 million |
| Profit attributable to owners of the parent | ¥37,369 million (YoY +3.1%) |
| Net income per share | ¥114.04 |
| Operating Margin | 16.4% |
| Equity ratio | End of the current fiscal period 70.2% / End of previous period 69.9% |
| Total assets | ¥423,033 million |
| Net assets | ¥296,017 million |
| Cash flows from operating activities | ¥43,500 million |
| Cash flows from investing activities | ¥-12,974 million |
| Cash flows from financing activities | ¥-49,348 million |
| Cash and cash equivalents at end of period | ¥80,875 million |
| Full-year earnings forecast | Net Sales ¥311,000 million (YoY +6.6%) / Operating profit ¥49,500 million (YoY +3.6%) / Ordinary income Not disclosed / Net income ¥40,000 million (YoY +7.0%) |
| Annual Dividend Forecast | ¥38 → ¥42（+10.5%） |
| Payout ratio | 33.8% |
| Shareholder Return Policy | Continue progressive dividends with the current level of ¥19 per half-year as the minimum, while also conducting opportunistic share buybacks |
| Regional sales | ¥146,812 million (YoY -11.2%), ¥30,011 million (YoY +0.5%), ¥33,252 million (YoY +14.0%), ¥80,097 million (YoY +7.8%), ¥1,451 million |
| Depreciation and amortization | ¥18,358 million |
| Impairment loss | ¥3,841 million |
| Breakdown of extraordinary income (loss) | Other income (IFRS) ¥6,978 million, Other expenses (IFRS) ¥4,395 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New No / Excluded No / Company name Not disclosed |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for securities analysts and institutional investors) |
| Issued Shares at Period-End | 322,281,654 shares |
| Treasury Shares at Period-End | 602,813 shares |
| Factors Behind Changes in Business Performance | Despite the impact of drug price revisions and other factors, the company focused on expanding new and core products. Core operating profit declined due to lower gross profit and higher selling, general and administrative expenses and research and development expenses. IFRS operating profit benefited from an increase in other income, but the company recorded impairment losses in connection with the discontinuation of development. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Despite the impact of drug price revisions and generic drugs, the company focused on expanding new and core products. Operating profit benefited from other income arising from the reclassification of translation differences related to foreign operations, but the company recorded impairment losses on intangible assets in connection with the discontinuation of development.